Janssen organizes a scientific symposium on Next-Generation Cell Therapy in Beerse, Belgium, on Thursday June 22, 2023. With advancements in technology and research, the next generation in cell therapies is emerging as a promising approach for effective treatment across a wide range of diseases.
Take part and gain insight into the current state-of-the-art research in next-generation cell-based therapies with a specific focus on allogeneic cell therapies and logic-gated chimeric antigen receptors. The symposium also aims to explore the challenges that lie ahead, including manufacturing.
Speakers include renowned academic experts Michael Hudecek (Universitätsklinikum Würzburg, Germany), Evren Alici (Karolinska Institute, Sweden), Michael Traxlmayr (University Vienna, Austria) and Maria Themeli (UMCAmsterdam, The Netherlands). On top of this, industry speakers Hermann Bohnenkamp from Miltenyi, Stefania Gobessi from Cell Point/Galapagos, Martin Pule from Autolus, Marcus Dangl from Evotec, Mark Davies from Leucid Bio, Michael Lanero Fidalgo from Treefrog Therapeutics, and Chuck Drake from Janssen (ImmunoOncology PAS, SH, USA) will share insights and latest developments in the field.
Upload your resume
Rodendijk 60 X
2980 Zoersel, Belgium
+32 (0) 3 296 01 51
General Inquiry: email@example.com
Job Opportunities: HR@2bridge.be
Service & Solution: BD@2bridge.be
2 Bridge NV is a recognized service provider for the KMO portefeuille (SME portfolio) for providing strategic advice(DV.A222333) and training (DV.O214140).
2 Bridge obtained the Crédit Impots Recherche (CIR) Accreditation for the years 2021, 2022, and 2023, an initiative of the French government to provide tax credit for R&D services.
© 2023 2 Bridge. website by EHBOntwerp